MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function

Phase 1
Completed
Conditions
Renal Insufficiency
Interventions
First Posted Date
2014-07-16
Last Posted Date
2014-07-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
51
Registration Number
NCT02191228

Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®

Completed
Conditions
HIV Infections
Interventions
First Posted Date
2014-07-16
Last Posted Date
2014-07-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
228
Registration Number
NCT02191293

Pharmacokinetic Study of Seresis® in the Skin in Healthy Young Female Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Seresis®
First Posted Date
2014-07-16
Last Posted Date
2014-07-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT02191852

Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-07-16
Last Posted Date
2014-07-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT02191176

Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation

Completed
Conditions
Myocardial Infarction
Interventions
First Posted Date
2014-07-16
Last Posted Date
2014-07-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
60
Registration Number
NCT02191670

Pharmacokinetics of Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-11
Last Posted Date
2014-07-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT02187536

Micardis® in Patients With Essential Hypertension

Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-07-11
Last Posted Date
2014-07-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1688
Registration Number
NCT02187705

Study to Assess the Kinetic of the Analgesic Effect and Tolerability of Eschscholtzia Californica Versus Ibuprofen and Placebo in the Treatment of Pain After Surgery of the Third Molar

Phase 2
Completed
Conditions
Pain
Interventions
Drug: Eschscholtzia Californica - high dose Placebo
Drug: Eschscholtzia Californica - low dose
Drug: Eschscholtzia Californica - high dose
Drug: Eschscholtzia Californica - low dose Placebo
First Posted Date
2014-07-11
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
200
Registration Number
NCT02187588

Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Telmisartan/HCTZ FDC
First Posted Date
2014-07-11
Last Posted Date
2014-07-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
32
Registration Number
NCT02187523

Pharmacokinetics of BIBR 277 in Hypertensive Patients

Phase 2
Completed
Conditions
Hypertension
Interventions
Drug: Medium dose of BIBR 277
Drug: Low dose of BIBR 277
Drug: High dose of BIBR 277
First Posted Date
2014-07-11
Last Posted Date
2014-07-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
93
Registration Number
NCT02187497
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy